급성 골수성 백혈병 시장 규모는 2023년에 7억 5,000만 달러로 평가되었고, 2029년까지의 예측 기간의 복합 연간 성장률(CAGR)은 8.70%를 나타낼 전망이며 눈부신 성장이 전망되고 있습니다.
| 시장 개요 | |
|---|---|
| 예측 기간 | 2025-2029년 |
| 시장 규모 : 2023년 | 7억 5,000만 달러 |
| 시장 규모 : 2029년 | 12억 2,000만 달러 |
| 복합 연간 성장률(CAGR) : 2024-2029년 | 8.70% |
| 급성장 부문 | 호르몬 요법 |
| 최대 시장 | 북미의 |
급성 골수성 백혈병(AML)은 골수와 혈액을 침범하는 암의 일종입니다. AML은 감염에 대항하고 산소를 운반하는 역할을 하는 미성숙한 백혈구인 비정상적인 골수계 세포의 급속한 증식을 특징으로 합니다. AML은 이러한 비정상적인 세포가 제대로 성숙하지 못하고 골수의 건강한 세포를 밀어 넣기 때문에 정상적인 혈액 세포의 생산을 감소시킵니다. 그 결과 다양한 증상과 합병증을 유발할 수 있습니다. AML은 피로, 탈력감, 빈혈(적혈구 수의 저하), 감염증에 걸리기 쉽고, 출혈하기 쉬워지고, 타박상이 생기기 쉽다(혈소판 수의 저하에 의한), 발열, 체중 감소 등 다양한 증상 발생합니다. 또한 뼈 통증을 경험하는 환자도 있습니다. 표적 요법과 면역 요법을 포함한 새롭고 개선된 치료법의 개발로 AML 환자가 사용할 수 있는 치료 옵션이 넓어졌습니다. 이러한 진보는 보다 효과적이고 맞춤 치료 접근법을 제공합니다.
AML 분야에서 지속적인 R&D 노력으로 새로운 치료 표적과 치료 전략이 발견되었습니다. 이 혁신은 투자를 불러들여 시장을 전진시키고 있습니다. 분자진단의 진보는 AML과 관련된 특정 유전자 변이 및 마커의 확인을 가능하게했습니다. 이로 인해 맞춤형 치료에 대한 길이 열리고 표적 치료에 대한 수요가 높아지고 있습니다. AML 치료를 위한 새로운 치료법을 승인하는 규제 기관은 이용 가능한 치료 옵션을 확대하고 환자 결과를 개선함으로써 시장 성장에 기여합니다. AML의 증상에 대한 인식이 향상되고 조기 진단의 중요성이 인식됨에 따라 더 많은 환자가 더 이른 단계에서 치료를 받게 되어 예후가 개선될 가능성이 있기 때문에 치료제 수요가 증가하고 있습니다.
치료 옵션의 진보
임상 연구 및 혁신
인지도와 조기 진단
환자 계층화를 위한 바이오마커의 부족
줄기세포 기증자 부족
환자 접근 및 합리적인 가격
Global Acute Myeloid Leukemia Market was valued at USD 0.75 billion in 2023 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 8.70% through 2029.
| Market Overview | |
|---|---|
| Forecast Period | 2025-2029 |
| Market Size 2023 | USD 0.75 Billion |
| Market Size 2029 | USD 1.22 Billion |
| CAGR 2024-2029 | 8. 70% |
| Fastest Growing Segment | Hormonal therapy |
| Largest Market | North America |
Acute Myeloid Leukemia (AML) is a type of cancer that affects the bone marrow and blood. It is characterized by the rapid growth of abnormal myeloid cells, which are immature white blood cells responsible for fighting infections and carrying oxygen. In AML, these abnormal cells do not mature properly and crowd out healthy cells in the bone marrow, leading to a decrease in the production of normal blood cells. This can result in a variety of symptoms and complications. AML can cause a range of symptoms, including fatigue, weakness, anemia (low red blood cell count), increased susceptibility to infections, bleeding or bruising easily (due to low platelet count), fever, and weight loss. Some patients may also experience bone pain. The development of new and improved therapies, including targeted therapies and immunotherapies, has expanded the treatment options available for AML patients. These advancements provide more effective and personalized treatment approaches.
Ongoing research and development efforts in the field of AML have led to the discovery of novel therapeutic targets and treatment strategies. This innovation attracts investment and drives the market forward. Advances in molecular diagnostics have enabled the identification of specific genetic mutations and markers associated with AML. This has paved the way for personalized treatment approaches, increasing the demand for targeted therapies. Regulatory agencies approving new therapies for AML treatment contribute to market growth by expanding the available treatment options and improving patient outcomes. Improved awareness of AML symptoms and the importance of early diagnosis has led to more patients seeking treatment at an earlier stage, potentially improving outcomes, and driving demand for therapies.
Key Market Drivers
Advancements in Treatment Options
The development of targeted therapies that focus on specific genetic mutations or molecular markers associated with AML has been a breakthrough. Drugs like "FLT3 inhibitors" and "IDH inhibitors" target specific mutations in leukemia cells, leading to more effective and tailored treatments. Immunotherapies, including monoclonal antibodies and checkpoint inhibitors, are being explored for their potential in AML treatment. These therapies harness the body's immune system to recognize and attack leukemia cells. The rise of precision medicine involves tailoring treatment based on a patient's unique genetic and molecular profile. This approach allows for personalized treatment strategies that have the potential to be more effective and less toxic.
Epigenetic changes play a significant role in AML development. Drugs that target these changes, such as "DNMT inhibitors" and "HDAC inhibitors," are being studied as potential treatments. Venetoclax, an inhibitor of BCL-2, has shown promise in combination with other therapies, particularly in older adults or those with certain genetic mutations. Advances in detecting very low levels of leukemia cells, known as MRD, have allowed for more accurate assessment of treatment response and adjustment of treatment strategies accordingly. Techniques for stem cell transplantation have improved, expanding the eligibility criteria, and reducing complications associated with the procedure. Researchers are investigating various combinations of chemotherapy, targeted therapies, and immunotherapies to enhance treatment efficacy while minimizing side effects. Advances in supportive care, such as anti-nausea medications and infection prevention strategies, have improved patients' ability to tolerate intensive treatments. This factor will help in the development of the global acute myeloid leukemia market.
Clinical Research and Innovation
Clinical research and innovative developments contribute to the evolution of treatment approaches, the introduction of new therapies, and improved patient outcomes. Clinical research leads to the discovery and development of new therapies, including targeted agents, immunotherapies, and other innovative treatment modalities. These novel therapies create new options for patients who may have exhausted traditional treatments. Through clinical trials, researchers can assess the efficacy of new treatments in comparison to existing therapies. Positive outcomes from these trials lead to increased adoption of the new treatments by healthcare providers, driving demand. Clinical research identifies genetic mutations and biomarkers associated with AML. This information enables personalized treatment approaches that target the specific characteristics of a patient's disease, increasing the demand for tailored therapies. Innovations in treatment contribute to improved survival rates among AML patients. Positive outcomes from clinical trials and real-world data encourage healthcare providers to adopt these treatments, increasing patient demand.
Robust clinical research attracts investments from pharmaceutical companies, biotech firms, and venture capitalists. The potential for innovative therapies in AML encourages funding and resources to be directed toward the development of these treatments. The participation of AML patients in clinical trials provides access to cutting-edge treatments that might not be available through standard care. This participation fosters patient demand for advanced therapies. Positive clinical trial outcomes often lead to regulatory approvals by health authorities such as the FDA and EMA. These approvals legitimize new therapies and encourage their adoption in clinical practice. Clinical research findings are shared through medical conferences, publications, and educational programs. Healthcare providers learn about new treatment options and are more likely to offer them to their patients. International collaborations among researchers, institutions, and pharmaceutical companies accelerate the pace of innovation. The collective effort contributes to the development of more effective treatments. Patients and advocacy groups are often strong advocates for clinical research and innovative treatments. Their efforts raise awareness, drive demand for research funding, and push for expedited access to promising therapies. This factor will pace up the demand of the global acute myeloid leukemia market.
Awareness and Early Diagnosis
Early diagnosis allows for timely initiation of treatment, which can lead to better treatment outcomes and increased chances of remission. As awareness spreads about the importance of early detection, more patients are likely to seek medical attention promptly. Raising awareness about AML symptoms, risk factors, and the benefits of early diagnosis can lead to a larger patient pool seeking medical evaluation. This, in turn, drives demand for diagnostic tests, treatments, and supportive care services. When AML is diagnosed at an earlier stage, patients may have a lower tumor burden, making treatments more effective. Early treatment can potentially reduce disease progression and the need for more aggressive therapies. Increased awareness may encourage individuals to adopt healthier lifestyles and seek routine check-ups, helping to identify potential risk factors and enabling early intervention to prevent the development of AML.
Heightened awareness empowers patients to recognize symptoms, communicate concerns with healthcare providers, and advocate for appropriate diagnostic tests and treatments. Awareness campaigns, educational programs, and patient advocacy efforts contribute to educating the public, healthcare professionals, and policymakers about AML, its symptoms, and the importance of early diagnosis. Early diagnosis may lead to less advanced disease stages, resulting in shorter hospital stays, fewer complications, and lower healthcare costs. This can drive healthcare systems to invest in early detection and management programs. As awareness increases, funding for research and innovation in AML diagnosis and treatment may also rise, stimulating advancements in diagnostics and therapies. International efforts to promote cancer awareness and early diagnosis contribute to the broader effort to improve cancer care, including AML, on a global scale. In some cases, increased awareness about AML can lead to the establishment of screening programs, allowing for early detection and intervention in high-risk populations. This factor will accelerate the demand of the global acute myeloid leukemia market.
Key Market Challenges
Lack of Biomarkers for Patient Stratification
Biomarkers are crucial indicators that help healthcare professionals predict disease behavior, determine treatment response, and tailor therapies to individual patients. In AML, the absence of reliable biomarkers for accurate patient stratification can impact treatment decisions and outcomes. Biomarkers help guide treatment decisions by identifying patients who are likely to respond to specific therapies. Without effective biomarkers, treatments may be less targeted, potentially leading to suboptimal outcomes. Biomarkers enable the development of targeted and personalized treatment strategies that are more effective and associated with fewer side effects. Biomarkers are essential in the development of new therapies. A lack of biomarkers can hinder the identification of patients who are most likely to benefit from a new drug, leading to challenges in clinical trial design and drug approvals. Biomarkers play a crucial role in patient enrollment and stratification in clinical trials. Without biomarkers, trials may include a heterogeneous patient population, making it challenging to interpret trial results accurately. Lack of biomarkers can lead to more generalized treatment guidelines rather than specific recommendations based on individual patient characteristics. The identification of biomarkers often directs research efforts toward understanding the underlying biology of AML, leading to potential breakthroughs in treatment strategies.
Limited Availability of Stem Cell Donors
Stem cell transplantation, which includes bone marrow and hematopoietic stem cell transplantation, is a potentially curative treatment option for many AML patients. However, finding a compatible donor can be complex and challenging. Stem cell transplantation requires a compatible donor, usually a family member or an unrelated donor with matching tissue types. The chances of finding a suitable donor decrease as the genetic diversity between patients and potential donors increases. AML affects people from diverse ethnic backgrounds, and ethnicity plays a crucial role in finding a compatible donor. Patients from minority groups may face greater difficulty in finding a matched donor due to the underrepresentation of certain ethnicities in donor registries. International registries of potential stem cell donors have been established to improve donor matching. However, these registries still face challenges in achieving a diverse representation of donors from different populations. In cases where a fully matched donor cannot be found, haploidentical transplantation from a partially matched family member is an option. However, this procedure may carry higher risks. Umbilical cord blood contains stem cells and can be used for transplantation. Cord blood banks have been established to provide another source of stem cells, but the quantity of cells in a single unit may not be sufficient for larger patients. AML treatment decisions are time-sensitive, and delays in finding a suitable donor can impact treatment outcomes and patient survival.
Key Market Trends
Patient Access and Affordability
Patient access and affordability are indeed important trends in the Global Acute Myeloid Leukemia (AML) Market. Ensuring that AML patients have access to appropriate treatments and therapies without facing financial hardships is crucial for equitable and effective healthcare delivery. Patient access ensures that all individuals, regardless of their socioeconomic status, can receive timely and appropriate AML treatments. Addressing disparities in access contributes to more equitable healthcare. Efforts to improve patient access often involve expanding the availability of approved treatments, including novel therapies, targeted agents, and innovative treatment modalities. The high costs associated with AML treatment can be a barrier to access. Market trends involve finding ways to make treatments more affordable through pricing strategies, insurance coverage, and patient assistance programs. Government and healthcare regulatory bodies may implement policies to enhance patient access and affordability, such as price controls or reimbursement adjustments for specific treatments. Ensuring that AML treatments are covered by insurance plans, including government-funded programs, can significantly improve patient access and alleviate financial burdens. Pharmaceutical companies and organizations often offer patient assistance programs that provide financial support to eligible patients who may struggle with the cost of treatments.
Segmental Insights
Chemotherapy Insights
In 2023, the Cytarabine segment is witnessing highest growth and is predicted to continue expanding over the coming years. Acute and chronic myelogenous leukaemia (AML and CML), acute lymphocytic leukaemia (ALL), and acute promyelocytic leukaemia (APL) are among the several leukaemia types that can be treated with cytarabine. Along with other lymphoma (cancers found in the lining of the brain and spinal cord), it can treat Hodgkin's lymphoma, meningeal leukaemia, and other forms of lymphoma. Cytarabine is frequently used during chemotherapy because it is useful in treating acute myeloid leukaemia. Cytarabine is frequently used because, according to cancer organisations like Macmillan Cancer Support, it is more effective against acute myeloid leukaemia. As a result, it is anticipated that this sub-segment will account for a sizeable portion of the chemotherapy market.
Regional Insights
The North America region dominated the Global Acute Myeloid Leukemia Market in 2023. This market in this region is anticipated to expand because of the increased incidence of acute myeloid leukaemia cases in the US. For instance, acute myeloid leukaemia is a rare cancer that makes up about 1% of all malignancies, according to the American Society of Clinical Oncology in 2021. In the US, this disease was thought to have affected 20,240 persons of all ages in 2021 (11,230 men and boys and 9,010 women and girls). AML is the second most common kind of leukaemia in both adults and children, with cases primarily affecting adults. Since acute myeloid leukaemia is becoming more common in the US, more people will likely use its treatments, which is predicted to fuel the market's expansion in North America. Rising R&D spending and new product introductions for acute myeloid leukaemia are also anticipated to fuel market expansion in this area.
Due to the expansion of government initiatives to raise public awareness, an increase in medical tourism, an increase in research activities in the region, the availability of sizable untapped markets, a sizable population pool, and the rising demand for high-quality healthcare in the region, Asia-Pacific is predicted to experience significant growth during the forecast period of 2023 to 2030.
Key Market Players
Bristol-Myers Squibb Company (Celgene Corporation)
Novartis AG
Genmab AS
Otsuka Holdings Co. Ltd
Sanofi-Aventis (Genzyme Corporation)
Teva Pharmaceutical (Cephalon Inc.)
Pfizer Inc.
F. Hoffmann-La Roche Ltd
Sunesis Pharmaceuticals Inc.
Astellas Pharma
Oncolyze Inc.
Syndax Pharmaceuticals Inc.
AbbVie Inc.
Amgen Inc.
Agios Pharmaceuticals Inc.
In this report, the Global Acute Myeloid Leukemia Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global Acute Myeloid Leukemia Market.
Global Acute Myeloid Leukemia Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Detailed analysis and profiling of additional market players (up to five).